PLEKHA5-L upregulates oncogenes (e.g., HRAS, AKT3) to enhance melanoma migration and proliferation, while concomitantly elevating the expression of therapy-resistance mediators PD-L1 and ABC transporters. Here, AKT3 is linked to melanoma.